Vortioxetine
Brand names: Brintellix, Trintellix
Vortioxetine is an antidepressant used to treat major depressive disorder in adults.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It inhibits the serotonin transporter while also acting as an agonist, partial agonist or antagonist at several serotonin receptor subtypes, producing a multimodal effect on serotonergic neurotransmission.
Prescribing in practice
- Carries a risk of serotonin syndrome, particularly when combined with other serotonergic agents or MAO inhibitors, which are contraindicated.
- Nausea is the most common adverse effect and tends to diminish over the first few weeks of treatment.
- Withdraw gradually where feasible and monitor for suicidal ideation, especially in younger adults during early treatment.
Monitoring
Monitor mood, response and emergence of suicidal ideation, especially during initiation and dose changes.
Counselling the patient
- It may take several weeks before the full antidepressant benefit is felt.
- Report any agitation, confusion, fever or muscle twitching promptly.
- Do not stop the medicine abruptly without medical advice.
Evidence & guidelines
NICE recommends antidepressants as an option for moderate to severe depression alongside psychological therapy.
Reference: Alvarez et al. Int J Neuropsychopharmacol 2014; McIntyre et al. J Psychopharmacol 2014 (FOCUS); NICE NG222; MHRA SPC Brintellix; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185